Bone Turnover Markers: A Clinical Review

Guañabens, Núria; Peris, Pilar; Monegal, Ana

doi:10.1007/s12018-015-9185-x

Cited by 5 publications

(3 citation statements)

References 107 publications

(168 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2c, d ). The upregulation of serum bone-resorption biomarkers 30 , CTX-I and TRAP5b, in Nron OCs−/− mice indicated that osteoclast-specific Nron knockout enhances bone-resorption activities of Nron OCs−/− mice (Fig. 2a ).…”

Section: Resultsmentioning

confidence: 97%

A functional motif of long noncoding RNA Nron against osteoporosis

Jin

Zhang

et al. 2021

Nat Commun

View full text Add to dashboard Cite

Long noncoding RNAs are widely implicated in diverse disease processes. Nonetheless, their regulatory roles in bone resorption are undefined. Here, we identify lncRNA Nron as a critical suppressor of bone resorption. We demonstrate that osteoclastic Nron knockout mice exhibit an osteopenia phenotype with elevated bone resorption activity. Conversely, osteoclastic Nron transgenic mice exhibit lower bone resorption and higher bone mass. Furthermore, the pharmacological overexpression of Nron inhibits bone resorption, while caused apparent side effects in mice. To minimize the side effects, we further identify a functional motif of Nron. The delivery of Nron functional motif to osteoclasts effectively reverses bone loss without obvious side effects. Mechanistically, the functional motif of Nron interacts with E3 ubiquitin ligase CUL4B to regulate ERα stability. These results indicate that Nron is a key bone resorption suppressor, and the lncRNA functional motif could potentially be utilized to treat diseases with less risk of side effects.

show abstract

Section: Resultsmentioning

confidence: 97%

A functional motif of long noncoding RNA Nron against osteoporosis

Jin

Zhang

et al. 2021

Nat Commun

View full text Add to dashboard Cite

show abstract

“…Among the indices of bone formation, the bone isoenzyme of alkaline phosphatase, osteocalcin and PINP are the most widely used. Several collagen degradation products, such as crosslaps (telopeptide of type I collagen), and TRAP5b, an enzyme highly expressed by osteoclasts, are some of the best known markers of bone resorption [15 ] .…”

Section: Bone Remodelingmentioning

confidence: 99%

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

López-Delgado¹,

Riancho‐Zarrabeitia²,

Riancho³

2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

“…New bone turnover markers were developed and measurements became more accurate. However, there is biological variability in BMTs due to age, sex, physical activity, recent fractures, or intercurrent disease ( 139 ). Due to these factors, interpretation of BMTs in rare metabolic bone disorders can be difficult.…”

Section: Discussionmentioning

confidence: 99%

A Clinical Perspective on Advanced Developments in Bone Biopsy Assessment in Rare Bone Disorders

et al. 2020

View full text Add to dashboard Cite

Introduction: Bone biopsies have been obtained for many centuries and are one of the oldest known medical procedures in history. Despite the introduction of new noninvasive radiographic imaging techniques and genetic analyses, bone biopsies are still valuable in the diagnosis of bone diseases. Advanced techniques for the assessment of bone quality in bone biopsies, which have emerged during the last decades, allows in-depth tissue analyses beyond structural changes visible in bone histology. In this review, we give an overview of the application and advantages of the advanced techniques for the analysis of bone biopsies in the clinical setting of various rare metabolic bone diseases. Method: A systematic literature search on rare metabolic bone diseases and analyzing techniques of bone biopsies was performed in PubMed up to 2019 week 34. Results: Advanced techniques for the analysis of bone biopsies were described for rare metabolic bone disorders including Paget's disease of bone, osteogenesis imperfecta, fibrous dysplasia, Fibrodysplasia ossificans progressiva, PLS3 X-linked osteoporosis, Loeys-Diets syndrome, osteopetrosis, Erdheim-Chester disease, and Cherubism. A variety of advanced available analytical techniques were identified that may help to provide additional detail on cellular, structural, and compositional characteristics in rare bone diseases complementing classical histopathology. Discussion: To date, these techniques have only been used in research and not in daily clinical practice. Clinical application of bone quality assessment techniques depends upon several aspects such as availability of the technique in hospitals, the existence of reference data, and a cooperative network of researchers and clinicians. The evaluation of rare metabolic bone disorders requires a repertoire of different methods, owing to their distinct bone tissue characteristics. The broader use of bone material obtained from biopsies could provide much more information about pathophysiology or treatment options and establish bone biopsies as a valuable tool in rare metabolic bone diseases.

show abstract

Bone Turnover Markers: A Clinical Review

Cited by 5 publications

References 107 publications

A functional motif of long noncoding RNA Nron against osteoporosis

A functional motif of long noncoding RNA Nron against osteoporosis

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

A Clinical Perspective on Advanced Developments in Bone Biopsy Assessment in Rare Bone Disorders

Contact Info

Product

Resources

About